$PRLD
Prelude Therapeutics Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021043718 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.513M $2.861M
YoY Change 92.69%
% of Gross Profit
Research & Development $22.41M $18.31M
YoY Change 22.37%
% of Gross Profit
Depreciation & Amortization $199.0K $270.0K
YoY Change -26.3% 68.75%
% of Gross Profit
Operating Expenses $27.92M $11.44M
YoY Change 144.16%
Operating Profit -$27.92M -$11.44M
YoY Change 144.16%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.057M $28.00K
YoY Change 3675.0%
Pretax Income -$26.87M -$20.92M
YoY Change 28.42%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$26.87M -$11.41M
YoY Change 135.49% 105.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58
Diluted Earnings Per Share -$0.58 -$4.899M
COMMON SHARES
Basic Shares Outstanding 46.06M
Diluted Shares Outstanding 46.06M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $343.1M $29.70M
YoY Change 1055.28%
Cash & Equivalents $343.1M $29.72M
Short-Term Investments
Other Short-Term Assets $1.456M $1.000M
YoY Change 45.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $344.6M $30.70M
YoY Change 1022.39%
LONG-TERM ASSETS
Property, Plant & Equipment $5.006M $1.600M
YoY Change 212.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $500.0K
YoY Change -100.0%
Total Long-Term Assets $5.006M $2.000M
YoY Change 150.3%
TOTAL ASSETS
Total Short-Term Assets $344.6M $30.70M
Total Long-Term Assets $5.006M $2.000M
Total Assets $349.6M $32.70M
YoY Change 969.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.844M $3.500M
YoY Change 95.54%
Accrued Expenses $6.430M $1.700M
YoY Change 278.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $14.68M $5.600M
YoY Change 162.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $543.0K $0.00
YoY Change
Total Long-Term Liabilities $543.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.68M $5.600M
Total Long-Term Liabilities $543.0K $0.00
Total Liabilities $15.22M $5.700M
YoY Change 167.02%
SHAREHOLDERS EQUITY
Retained Earnings -$155.6M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $334.4M -$69.31M
YoY Change
Total Liabilities & Shareholders Equity $349.6M $32.70M
YoY Change 969.06%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$26.87M -$11.41M
YoY Change 135.49% 105.33%
Depreciation, Depletion And Amortization $199.0K $270.0K
YoY Change -26.3% 68.75%
Cash From Operating Activities -$19.92M -$18.82M
YoY Change 5.82% 62.66%
INVESTING ACTIVITIES
Capital Expenditures -$377.0K -$120.0K
YoY Change 214.17% -14.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$377.0K -$120.0K
YoY Change 214.17% -14.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 422.0K 29.78M
YoY Change -98.58% -0.23%
NET CHANGE
Cash From Operating Activities -19.92M -18.82M
Cash From Investing Activities -377.0K -120.0K
Cash From Financing Activities 422.0K 29.78M
Net Change In Cash -19.87M 10.84M
YoY Change -283.3% -40.24%
FREE CASH FLOW
Cash From Operating Activities -$19.92M -$18.82M
Capital Expenditures -$377.0K -$120.0K
Free Cash Flow -$19.54M -$18.70M
YoY Change 4.48% 63.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M17D
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000
us-gaap Share Based Compensation
ShareBasedCompensation
8123000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26865000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11408000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1044000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-364000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3327000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1134000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-856000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-658000
prld Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
459000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36055000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18823000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
212183000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5513000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1660000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
27922000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11436000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27922000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11436000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1057000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.50
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46057112
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2074108
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
386000
CY2021Q1 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
739000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161412000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3886000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21300000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
356567000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4237000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26865000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
334361000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49412000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
362000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9511000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-58561000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
627000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11408000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-69311000
us-gaap Profit Loss
ProfitLoss
-48165000
us-gaap Profit Loss
ProfitLoss
-20919000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
359000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
267000
prld Noncash Lease Expense
NoncashLeaseExpense
572000
us-gaap Share Based Compensation
ShareBasedCompensation
989000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1367000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1367000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161424000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
191000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
808000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
162232000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29782000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
124810000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10837000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18879000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
343119000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29716000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
386000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
73000
prld Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
290000
prld Offering Costs In Accrued Expenses And Other Current Liabilities
OfferingCostsInAccruedExpensesAndOtherCurrentLiabilities
185000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155600000
CY2021Q2 prld Offset Accrued Expense And Other Current Liabilities To Eliminate Deferred Rent
OffsetAccruedExpenseAndOtherCurrentLiabilitiesToEliminateDeferredRent
64000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7636403
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31981924
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.26%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying unaudited interim financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p>
prld Operating Lease Estimated Incremental Borrowing Rate Percent
OperatingLeaseEstimatedIncrementalBorrowingRatePercent
0.100
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2330000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3614000
CY2021Q2 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
4071000
CY2020Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
3421000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
420000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6430000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
This option to extend was not recognized as part of the Company’s measurement of the right-of-use asset and operating lease liability as of June 30, 2021
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6839091
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2021Q2 prld Lease Commencement Date
LeaseCommencementDate
2021-07-01
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-06-30
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
702000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1403000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2105000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
159000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1946000
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2021Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
prld Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4237000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
627000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8123000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
989000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
423395
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
45.30
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
458060
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34988
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
43.36
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6769438
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.04
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1255060
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.21
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131100000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
33200000
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6769438
CY2021Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1255060

Files In Submission

Name View Source Status
0001564590-21-043718-index-headers.html Edgar Link pending
0001564590-21-043718-index.html Edgar Link pending
0001564590-21-043718.txt Edgar Link pending
0001564590-21-043718-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
prld-10q_20210630.htm Edgar Link pending
prld-10q_20210630_htm.xml Edgar Link completed
prld-20210630.xsd Edgar Link pending
prld-20210630_cal.xml Edgar Link unprocessable
prld-20210630_def.xml Edgar Link unprocessable
prld-20210630_lab.xml Edgar Link unprocessable
prld-20210630_pre.xml Edgar Link unprocessable
prld-ex311_7.htm Edgar Link pending
prld-ex312_6.htm Edgar Link pending
prld-ex321_9.htm Edgar Link pending
prld-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending